67858-48-4Relevant academic research and scientific papers
Novel irreversible covalent BTK inhibitors discovered using DNA-encoded chemistry
Guilinger, John P.,Archna, Archna,Augustin, Martin,Bergmann, Andreas,Centrella, Paolo A.,Clark, Matthew A.,Cuozzo, John W.,D?ther, Maike,Guié, Marie-Aude,Habeshian, Sevan,Kiefersauer, Reiner,Krapp, Stephan,Lammens, Alfred,Lercher, Lukas,Liu, Julie,Liu, Yanbin,Maskos, Klaus,Mrosek, Michael,Pflügler, Klaus,Siegert, Markus,Thomson, Heather A.,Tian, Xia,Zhang, Ying,Konz Makino, Debora L.,Keefe, Anthony D.
supporting information, (2021/06/15)
Libraries of DNA-Encoded small molecules created using combinatorial chemistry and synthetic oligonucleotides are being applied to drug discovery projects across the pharmaceutical industry. The majority of reported projects describe the discovery of reve
Novel pyrazolopiperazinone- and pyrrolopiperazinone-based MCH-R1 antagonists
Meyers, Kenneth M.,Mendez-Andino, Jose,Colson, Anny-Odile,Hu, X. Eric,Wos, John A.,Mitchell, Maria C.,Hodge, Karen,Howard, Jeremy,Paris, Jennifer L.,Dowty, Martin E.,Obringer, Cindy M.,Reizes, Ofer
, p. 657 - 661 (2007/10/03)
The synthesis and biological testing of novel classes of potent melanin-concentrating hormone (MCH-R1) antagonists based on pyrazolopiperazinone and pyrrolopiperazinone scaffolds are described.
Synthesis and characterization of Boc-protected 4-amino- and 5-amino-pyrrole-2-carboxylic acid methyl esters
Chakraborty, Tushar Kanti,Udawant, Sandip P.,Roy, Saumya,Mohan, Bajjuri Krishna,Rao, Kolla Srinivasa,Dutta, Samit Kumar,Kunwar, Ajit Chand
, p. 4631 - 4634 (2007/10/03)
Syntheses of Boc-protected 4-amino- and 5-amino-pyrrole-2-carboxylic acid methyl esters have been achieved and the structures of these compounds have been fully characterized by detailed NMR studies.
Pyrrole-derivatives as factor Xa inhibitors
-
Page/Page column 46, (2008/06/13)
The present invention relates to compounds of the formulae I and Ia, wherein R0 ; R1 ; R2 ; R3 ; R4; R22, Q; V, G and M have the meanings indicated in the claims. The compounds of the formulae I and Ia are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formulae I and Ia, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
